Chengdu Kanghong Pharmaceutical Group (002773.SZ): Hongji Biological's self-developed AAV gene therapy product KHN921 injection has been approved for clinical trials of drugs.

Chengdu Kanghong Pharmaceutical Group (002773.SZ) announced that its subsidiary Chengdu Hongji Bio-Tech Co., Ltd. (hereinafter referred to as "Hongji Bio") has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the drug KHN921 injection. KHN921 injection is an AAV gene therapy product independently developed by Hongji Bio, used for treating hypertrophic cardiomyopathy caused by MYBPC3 mutation. In April 2026, an email was received from the U.S. Food and Drug Administration approving the clinical trial of KHN921 injection in the United States. This product uses a novel adenovirus vector based on the company's proprietary knowledge, designed with cell-specific receptors, and employs an innovative drug delivery method to achieve precise targeting and efficient transduction of myocardial tissue. By delivering the functional target gene to the patient's myocardial cells through AAV vectors, the product corrects functional defects caused by pathogenic gene mutations at the genetic level, improves myocardial structure and function, delays or reverses disease progression, and reduces the risk of serious cardiovascular events.